Survey of Incidence of Respiratory Tract Infections

NCT06649032 — Completed, 1736 participants, Lallemand Pharma AG

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

A Multicentric Epidemiological Study of the Actual Incidence of Respiratory Tract Infections in an Adult Italian Population, With or Without Underlying Risk Factors

Registry	NCT06649032, acronym SIRTI
Status	Completed
Study type	Observational
Enrollment	1736 (Actual)
Sponsor	Lallemand Pharma AG (Industry); collaborators: Istituto di Farmacologia Traslazionale - National Research Council (IFT-CNR)
Conditions	Healthy Adults, Not Healthy Adults
Interventions	No intervention (Other)
Dates	start 2023-11-07, primary completion 2025-05-31, completion 2025-07-17, first posted 2024-10-18, last updated 2025-08-11
Locations	23 sites in Italy

-Summary

The purpose of this study is to acquire reliable and current data on the actual incidence (post-COVID) of respiratory tract infections in the general adult population in the absence of any intervention. These data will provide useful background information for designing future studies aimed at assessing whether preventive measures or pharmacological treatments are beneficial in reducing the frequency and severity of infectious episodes.

Expand all sections · Collapse all

+Detailed description

This multicentric prospective observational survey will be carried out in Italy during the winter and early spring ( December 22nd to April 30th) in two consecutive years on approximately 2750 subjects recruited in the period between November 1st and December 21st in different medical settings and regions.

Investigators from 4 different institutions will be involved:

FIMMG (Federazione Italiana dei Medici di Medicina Generale). Ten general practitioners will recruit approx. 1000 consecutive subjects from the general population.

SIAAIC (Societa' Italiana di Allergologia, Asma e Immunologia Clkinica). Ten allergy specialists will recruit approx.1000 consecutive subjects suffering from allergic diseases.

Fondazione Maugeri (5 Centers) and UCSC (Universita' Cattolica del Sacro Cuore) / Policlinico Gemelli will recruit approx. 750 consecutive subjects suffering from asthma or COPD.

Participants having signed an informed consent at any suspected Respiratory Tract Infection (RTI) during the observation period will be asked to contact (phone call or visit) the investigator to record the relevant clinical information documenting the RTI episode.

At the end of the observation period all subjects will be contacted by the investigators to check for completeness and compliance of the RTI reporting.

The procedure will be repeated in the same way in the second year of survey but including subjects having experienced at least one confirmed RTI during the first year. This will allow assessing intra-individual variability of infectious episodes from year to year.

+Arms and interventions

Arm	Type	Interventions	Description
Cohort Incidence		Other: No intervention	This cohort will comprise subjects recruited from 1st November 2023 to 21st December 2023 and followed from 22nd December 2023 to 30th April 2024 and subjects recruited from 01st November 2024 to 21st December 2024 and followed from 22nd Dec 2024 to 30th April 2025. During the follow-up period, the subjects will be asked to report respiratory tract infections to the investigators (phone calls or study visit).
Cohort Respiratory Tract Infections (RTI) positive		Other: No intervention	Subjects recruited from 1st November 2023 to 21st December 2023, followed from 22nd December 2023 to 30th April 2024 and who developed at least one respiratory tract infection will be also followed from 22nd December 2024 to 30th April 2025 and asked to report respiratory tract infections to the investigators.

No intervention (Other): no difference: both cohorts are followed in the same way

+Outcome measures

Primary outcomes

Incidence of respiratory tract infections during the whole observation period (whole population, with risk factor, without risk factor) [From 22nd Dec 2023 to 30th Apr2024 and from 22nd Dec 2024 to 30th Apr 2025]: Overall mean number of respiratory tract infections during both observation periods (whole period), mean number of respiratory tract infections for subjects with or without risk factors during the whole period.

Secondary outcomes

Number of subjects of the Cohort Incidence with at least one respiratory tract infection during the first observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024]
Number of subjects of the Cohort Incidence with at least one respiratory tract infection during the second observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2024 to 30th Apr 2025]
Number of subjects from the Cohort RTI positive who had at least one respiratory tract infection during the second observation period [From 22nd Dec 2024 to 30th Apr 2025]
Total and mean number of respiratory tract infections during the first observation period for subjects belonging to the Cohort Incidence (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024]
Total and mean number of respiratory tract infections during the second observation period for subjects belonging to the Cohort Incidence (whole population, with risk factor, without risk factor) [from 22nd Dec 2024 to 30th Apr 2025]
Comparaison of the mean number of respiratory tract infections during the first observation period versus the second one for subjects belonging to the Cohort RTI positive (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]
Total and mean number of respiratory tract infections during the first observation period for subjects belonging to the Cohort RTI positive (whole population, with risk factor, without risk factor [from 22nd Dec 2023 to 30th Apr 2024]
Total and mean number of respiratory tract infections during the second observation period for subjects belonging to the Cohort RTI positive (whole population, with risk factor, without risk factor) [from 22nd Dec 2024 to 30th Apr 2025]
Total and mean number of respiratory tract infections during the whole observation period for subjects belonging to the Cohort RTI positive (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]
Time to first respiratory infection during the first observation period (whole population, with risk factor, without risk factor) for subjects of the Cohort Incidence [from 22nd Dec 2023 to 30th Apr 2024]
Time to first respiratory infection of the subjects belonging to the Cohort Incidence during the second observation period (whole population, with risk factor, without risk factor [from 22nd Dec 2024 to 30th Apr 2025]
Time to first respiratory tract infection in the subjects belonging to the Cohort Incidence during the whole observation period (whole population, with risk factor, without risk factor [023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025 from 22nd Dec 2]
Comparaison of the mean number of respiratory tract infections during the first observation period versus the second one for subjects belonging to the Cohort Incidence (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]
Number of subjects of the Cohort RTI positive with recurrent respiratory tract infections (≥2) during each consecutive observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]
Number of subjects in both cohorts who were treated with antibiotics/antivirals during respiratory tract infections of the whole observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]
Number of subjects in both cohorts who were treated with antibiotics/antivirals during respiratory tract infections of the first observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024]
Number of subjects in both cohorts who were treated with antibiotics/antivirals during respiratory tract infections of the second observation period (whole population, with risk factor, without risk factor) [from 22nd Dec 2024 to 30th Apr 2025]
Description of severity of respiratory tract infections during the whole observation period in both cohorts (whole population, with risk factor, without risk factor) [from 22nd Dec 2023 to 30th Apr 2024 and from 22nd Dec 2024 to 30th Apr 2025]

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

Male or female aged from at least 18 years -

Exclusion Criteria:

Minor subjects-

+Locations (23)

Facility	City	Country
Dr F Pugliese	Bari	Italy
Università degli Studi di Cagliari	Cagliari	Italy
Università degli studi di salerno	Fisciano	Italy
Azienda Ospedaliero-Universitaria Careggi	Florence	Italy
Dr M D'Onofrio	Naples	Italy
Azienda Ospedale Università Padova	Padova	Italy
Azienda Ospedale-Università Padova	Padova	Italy
Dr F Gatti	Parma	Italy
A.S.L. di Pescara - Abruzzo	Popoli	Italy
Dr F R Amorosi	Roma	Italy
Dr G Marrocco	Roma	Italy
Dr S Narzisi	Roma	Italy
Dr A Galli	Roma	Italy
Dr C Governale	Roma	Italy
Dr E Meco	Roma	Italy
Dr A M Pistuddi	Roma	Italy
Dr R Chini	Roma	Italy
Università Cattolica del Sacro Cuore	Roma	Italy
Dr G Biondi	Roma	Italy
Dr C Nicoletta	Salerno	Italy
Azienda Ospedaliera Mauriziano di Torino	Torino	Italy
ASST dei Sette Laghi	Varese	Italy
ASP Vibo Valentia	Vibo Valentia	Italy

+Investigators

Sergio Bonini, Professor, Principal investigator, Institute of Translational Pharmacology, Italian National Research Council (IFT-CNR)